...
首页> 外文期刊>European Journal of Pharmacology: An International Journal >Time-dependent effects of escitalopram on brain derived neurotrophic factor (BDNF) and neuroplasticity related targets in the central nervous system of rats.
【24h】

Time-dependent effects of escitalopram on brain derived neurotrophic factor (BDNF) and neuroplasticity related targets in the central nervous system of rats.

机译:依他普仑对大鼠中枢神经系统脑源性神经营养因子(BDNF)和神经可塑性相关靶标的时间依赖性作用。

获取原文
获取原文并翻译 | 示例

摘要

Chronic treatment with antidepressants affects several proteins linked to neuroplasticity, particularly brain derived neurotrophic factor (BDNF): this leads eventually to their therapeutic effects. It is possible that also for putative early therapeutic onset, antidepressants may act by promoting cellular adaptations linked to neuroplasticity. Escitalopram, known to be already effective in preclinical models of depression after 7 days, allowed us to investigate whether two effective treatment regimens (7 and 21 days) may contribute to synaptic plasticity by acting on BDNF signalling. We focused our attention on two regulators of BDNF transcription, CREB and CaRF (calcium responsive factor), and on kinases, CaMKII, ERK1/2 and p38 MAPK, linked to BDNF that play a distinctive role in synaptic plasticity. We evaluated whether the effects of escitalopram on these targets may be different in brain areas involved in the depressive symptomatology (hippocampus, frontal and prefrontal cortex). Here we demonstrate that escitalopram regulates intracellular pathways linked to neuroplasticity at both the time points evaluated in an area-specific manner. While the two escitalopram-treatment regimens failed to affect gene expression in the rat frontal cortex, 7days of treatment with escitalopram activated intracellular pathways linked to BDNF and increased the levels of Pro-BDNF in the rat prefrontal cortex. Moreover, 21 days of treatment with escitalopram decreased CREB/BDNF signalling while increasing p38 levels in the rat hippocampus. Even if further experiments with different antidepressant strategies will be needed, our data suggest that escitalopram efficacy may be mediated by early and late effects on synaptic plasticity in selective brain areas.
机译:长期用抗抑郁药治疗会影响与神经可塑性相关的几种蛋白质,尤其是脑源性神经营养因子(BDNF):这最终导致其治疗效果。对于可能的早期治疗发作,抗抑郁药也可能通过促进与神经可塑性相关的细胞适应而发挥作用。 Escitalopram已知在7天后的抑郁症临床前模型中已经有效,它使我们能够研究两种有效的治疗方案(7天和21天)是否可以通过作用于BDNF信号来促进突触可塑性。我们将注意力集中在BDNF转录的两个调节剂CREB和CaRF(钙反应因子)上,以及与BDNF相关的激酶CaMKII,ERK1 / 2和p38 MAPK上,它们在突触可塑性中起着独特的作用。我们评估了依西酞普兰对这些靶标的作用在涉及抑郁症状的大脑区域(海马,额叶和额叶前皮层)是否可能有所不同。在这里,我们证明依他普仑在以区域特异性方式评估的两个时间点均调节与神经可塑性相关的细胞内途径。尽管两种依他普仑治疗方案均未影响大鼠额叶皮质的基因表达,但依他普仑治疗7天后激活了与BDNF相关的细胞内途径,并增加了大鼠前额叶皮质中Pro-BDNF的水平。此外,艾司西酞普兰治疗21天可降低CREB ​​/ BDNF信号传导,同时增加大鼠海马中的p38水平。即使需要使用不同的抗抑郁策略进行进一步的实验,我们的数据表明依他普仑的疗效可能是由选择性大脑区域对突触可塑性的早期和晚期影响介导的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号